BARD1 has an experienced board and management team with a track record in building successful companies, and international expertise in BARD1 biology, biomarker translation and respiratory medicine.
Peter Gunzburg BCom | Executive Chairman
Peter Gunzburg is a public company director, stockbroker and technology investor, with over 20 years corporate advisory, capital raising, transaction and business management experience. Peter has previously been a director of Resolute Ltd, Australian Stock Exchange Ltd, Eyres Reed Ltd, CIBC World Markets Australia Ltd, Fleetwood Corporation Ltd and Dragon Mining Ltd.
Dr Irmgard Irminger-Finger PD PhD | Executive Director & Chief Scientific Officer
Dr Irminger-Finger is founder and co-inventor of BARD1 and its technology. She has more than 15 years of experience in biotech as founder, director, and chair, as recipient of Swiss start up awards, and as one of five finalists of the 2014 European Woman Entrepreneur Award. She is an internationally recognised expert in tumor biology with over 100 publications, multiple international collaborations and many keynote presentations at international conferences. Irmgard has a Masters degree in molecular biology and a PhD in molecular genetics from the University of Zurich, and was an award research fellow at the Harvard University. She holds a tenured faculty position at the University (UNIGE) and University Hospital of Geneva (HUG) and Adjunct Professorship at the University of Western Australia (UWA).
Brett Montgomery | Non-Executive Director
Brett Montogomery has extensive experience in public company management, leadership, corporate governance and risk management. Brett is currently Non-Executive Director of Tanami Gold NL, and Magnum Gas and Power Ltd. He was previously Managing Director of Kalimantan Gold NL, and Director of Grants Patch Mining Ltd and EZA Corporation Ltd.
Dr Leearne Hinch BSc BVMS MBA | Chief Executive Officer
Dr Leearne Hinch is a biotechnology executive and consultant with extensive experience in the life science industry in general management, strategy, fundraising, business development and commercialisation. Leearne has strategic, operational and technical experience leading and managing the development and commercialisation of drug, device and animal health products. She is director of commercialisation advisory Ingeneus Solutions, and previously held CEO and executive positions in ASX-listed biotechnology, multinational and private companies including Eustralis Pharmaceuticals Ltd, Immuron Ltd, OBJ Ltd, Holista CollTech Ltd, Chemeq Ltd and Virbac (Australia) Pty Ltd.